nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP3A4—Everolimus—kidney cancer	0.0829	0.191	CbGbCtD
Sitaxentan—CYP3A4—Temsirolimus—kidney cancer	0.056	0.129	CbGbCtD
Sitaxentan—CYP2C9—Capecitabine—kidney cancer	0.0528	0.122	CbGbCtD
Sitaxentan—CYP2C19—Sorafenib—kidney cancer	0.0353	0.0814	CbGbCtD
Sitaxentan—CYP2C9—Paclitaxel—kidney cancer	0.033	0.0762	CbGbCtD
Sitaxentan—CYP3A4—Pazopanib—kidney cancer	0.0294	0.0678	CbGbCtD
Sitaxentan—CYP2C9—Sorafenib—kidney cancer	0.0293	0.0677	CbGbCtD
Sitaxentan—CYP3A4—Erlotinib—kidney cancer	0.021	0.0484	CbGbCtD
Sitaxentan—CYP3A4—Paclitaxel—kidney cancer	0.0192	0.0443	CbGbCtD
Sitaxentan—CYP3A4—Sorafenib—kidney cancer	0.0171	0.0394	CbGbCtD
Sitaxentan—CYP3A4—Vinblastine—kidney cancer	0.0168	0.0389	CbGbCtD
Sitaxentan—CYP3A4—Vincristine—kidney cancer	0.0166	0.0382	CbGbCtD
Sitaxentan—CYP3A4—Sunitinib—kidney cancer	0.0138	0.0319	CbGbCtD
Sitaxentan—CYP3A4—Doxorubicin—kidney cancer	0.0104	0.0239	CbGbCtD
Sitaxentan—CYP2C19—urine—kidney cancer	0.00406	0.201	CbGeAlD
Sitaxentan—CYP2C9—urine—kidney cancer	0.00315	0.156	CbGeAlD
Sitaxentan—EDNRB—cortex of kidney—kidney cancer	0.00265	0.131	CbGeAlD
Sitaxentan—EDNRB—cardiac atrium—kidney cancer	0.00252	0.125	CbGeAlD
Sitaxentan—CYP3A4—urine—kidney cancer	0.0024	0.119	CbGeAlD
Sitaxentan—EDNRA—cortex of kidney—kidney cancer	0.00219	0.108	CbGeAlD
Sitaxentan—EDNRA—cardiac atrium—kidney cancer	0.00208	0.103	CbGeAlD
Sitaxentan—CYP3A4—renal system—kidney cancer	0.000587	0.029	CbGeAlD
Sitaxentan—CYP3A4—kidney—kidney cancer	0.000567	0.0281	CbGeAlD
Sitaxentan—Rash—Everolimus—kidney cancer	9.77e-05	0.000212	CcSEcCtD
Sitaxentan—Dermatitis—Everolimus—kidney cancer	9.76e-05	0.000212	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	9.75e-05	0.00115	CbGpPWpGaD
Sitaxentan—Headache—Vinblastine—kidney cancer	9.75e-05	0.000211	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CTNNA1—kidney cancer	9.73e-05	0.00115	CbGpPWpGaD
Sitaxentan—Headache—Everolimus—kidney cancer	9.71e-05	0.00021	CcSEcCtD
Sitaxentan—Hypotension—Gemcitabine—kidney cancer	9.71e-05	0.00021	CcSEcCtD
Sitaxentan—Body temperature increased—Dactinomycin—kidney cancer	9.69e-05	0.00021	CcSEcCtD
Sitaxentan—Visual impairment—Capecitabine—kidney cancer	9.68e-05	0.00021	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—EIF4EBP1—kidney cancer	9.68e-05	0.00114	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HSPB1—kidney cancer	9.68e-05	0.00114	CbGpPWpGaD
Sitaxentan—Asthenia—Sorafenib—kidney cancer	9.65e-05	0.000209	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	9.62e-05	0.00113	CbGpPWpGaD
Sitaxentan—Malaise—Paclitaxel—kidney cancer	9.61e-05	0.000208	CcSEcCtD
Sitaxentan—Cardiac failure—Doxorubicin—kidney cancer	9.59e-05	0.000208	CcSEcCtD
Sitaxentan—Hypoglycaemia—Doxorubicin—kidney cancer	9.59e-05	0.000208	CcSEcCtD
Sitaxentan—Vertigo—Paclitaxel—kidney cancer	9.57e-05	0.000208	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	9.56e-05	0.00113	CbGpPWpGaD
Sitaxentan—Leukopenia—Paclitaxel—kidney cancer	9.54e-05	0.000207	CcSEcCtD
Sitaxentan—Hypersensitivity—Sunitinib—kidney cancer	9.54e-05	0.000207	CcSEcCtD
Sitaxentan—Decreased appetite—Vincristine—kidney cancer	9.52e-05	0.000206	CcSEcCtD
Sitaxentan—Vomiting—Erlotinib—kidney cancer	9.51e-05	0.000206	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Vincristine—kidney cancer	9.45e-05	0.000205	CcSEcCtD
Sitaxentan—Fatigue—Vincristine—kidney cancer	9.44e-05	0.000205	CcSEcCtD
Sitaxentan—Rash—Erlotinib—kidney cancer	9.43e-05	0.000204	CcSEcCtD
Sitaxentan—Dermatitis—Erlotinib—kidney cancer	9.42e-05	0.000204	CcSEcCtD
Sitaxentan—Insomnia—Gemcitabine—kidney cancer	9.4e-05	0.000204	CcSEcCtD
Sitaxentan—Eye disorder—Capecitabine—kidney cancer	9.39e-05	0.000204	CcSEcCtD
Sitaxentan—Headache—Erlotinib—kidney cancer	9.37e-05	0.000203	CcSEcCtD
Sitaxentan—Tinnitus—Capecitabine—kidney cancer	9.37e-05	0.000203	CcSEcCtD
Sitaxentan—Pain—Vincristine—kidney cancer	9.36e-05	0.000203	CcSEcCtD
Sitaxentan—Constipation—Vincristine—kidney cancer	9.36e-05	0.000203	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	9.36e-05	0.000203	CcSEcCtD
Sitaxentan—Osteoarthritis—Doxorubicin—kidney cancer	9.36e-05	0.000203	CcSEcCtD
Sitaxentan—Cardiac disorder—Capecitabine—kidney cancer	9.32e-05	0.000202	CcSEcCtD
Sitaxentan—Flushing—Capecitabine—kidney cancer	9.32e-05	0.000202	CcSEcCtD
Sitaxentan—Asthenia—Sunitinib—kidney cancer	9.29e-05	0.000201	CcSEcCtD
Sitaxentan—Nausea—Vinblastine—kidney cancer	9.24e-05	0.0002	CcSEcCtD
Sitaxentan—Somnolence—Gemcitabine—kidney cancer	9.23e-05	0.0002	CcSEcCtD
Sitaxentan—Migraine—Doxorubicin—kidney cancer	9.21e-05	0.0002	CcSEcCtD
Sitaxentan—Nausea—Everolimus—kidney cancer	9.21e-05	0.0002	CcSEcCtD
Sitaxentan—Diarrhoea—Sorafenib—kidney cancer	9.21e-05	0.0002	CcSEcCtD
Sitaxentan—Angiopathy—Capecitabine—kidney cancer	9.11e-05	0.000198	CcSEcCtD
Sitaxentan—Immune system disorder—Capecitabine—kidney cancer	9.07e-05	0.000197	CcSEcCtD
Sitaxentan—Chest pain—Paclitaxel—kidney cancer	9.07e-05	0.000197	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	9.05e-05	0.00107	CbGpPWpGaD
Sitaxentan—Mediastinal disorder—Capecitabine—kidney cancer	9.05e-05	0.000196	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CASP2—kidney cancer	9.04e-05	0.00106	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKAP13—kidney cancer	9.04e-05	0.00106	CbGpPWpGaD
Sitaxentan—Decreased appetite—Gemcitabine—kidney cancer	9.03e-05	0.000196	CcSEcCtD
Sitaxentan—Hypersensitivity—Dactinomycin—kidney cancer	9.03e-05	0.000196	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	9.01e-05	0.000195	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PSMD7—kidney cancer	9e-05	0.00106	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TSC1—kidney cancer	9e-05	0.00106	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ANXA1—kidney cancer	9e-05	0.00106	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.97e-05	0.000194	CcSEcCtD
Sitaxentan—Discomfort—Paclitaxel—kidney cancer	8.96e-05	0.000194	CcSEcCtD
Sitaxentan—Fatigue—Gemcitabine—kidney cancer	8.96e-05	0.000194	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	8.93e-05	0.00105	CbGpPWpGaD
Sitaxentan—Dizziness—Sorafenib—kidney cancer	8.9e-05	0.000193	CcSEcCtD
Sitaxentan—Constipation—Gemcitabine—kidney cancer	8.88e-05	0.000193	CcSEcCtD
Sitaxentan—Pain—Gemcitabine—kidney cancer	8.88e-05	0.000193	CcSEcCtD
Sitaxentan—Nausea—Erlotinib—kidney cancer	8.88e-05	0.000193	CcSEcCtD
Sitaxentan—Alopecia—Capecitabine—kidney cancer	8.88e-05	0.000192	CcSEcCtD
Sitaxentan—Dry mouth—Paclitaxel—kidney cancer	8.87e-05	0.000192	CcSEcCtD
Sitaxentan—Diarrhoea—Sunitinib—kidney cancer	8.86e-05	0.000192	CcSEcCtD
Sitaxentan—Ataxia—Doxorubicin—kidney cancer	8.8e-05	0.000191	CcSEcCtD
Sitaxentan—Mental disorder—Capecitabine—kidney cancer	8.8e-05	0.000191	CcSEcCtD
Sitaxentan—Asthenia—Dactinomycin—kidney cancer	8.79e-05	0.000191	CcSEcCtD
Sitaxentan—Confusional state—Paclitaxel—kidney cancer	8.77e-05	0.00019	CcSEcCtD
Sitaxentan—Blood creatinine increased—Doxorubicin—kidney cancer	8.77e-05	0.00019	CcSEcCtD
Sitaxentan—Malnutrition—Capecitabine—kidney cancer	8.74e-05	0.00019	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	8.71e-05	0.00103	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FLT1—kidney cancer	8.71e-05	0.00103	CbGpPWpGaD
Sitaxentan—Dehydration—Doxorubicin—kidney cancer	8.7e-05	0.000189	CcSEcCtD
Sitaxentan—Oedema—Paclitaxel—kidney cancer	8.7e-05	0.000189	CcSEcCtD
Sitaxentan—Body temperature increased—Vincristine—kidney cancer	8.66e-05	0.000188	CcSEcCtD
Sitaxentan—Liver function test abnormal—Doxorubicin—kidney cancer	8.64e-05	0.000187	CcSEcCtD
Sitaxentan—Infection—Paclitaxel—kidney cancer	8.64e-05	0.000187	CcSEcCtD
Sitaxentan—Dry skin—Doxorubicin—kidney cancer	8.58e-05	0.000186	CcSEcCtD
Sitaxentan—Dizziness—Sunitinib—kidney cancer	8.56e-05	0.000186	CcSEcCtD
Sitaxentan—Feeling abnormal—Gemcitabine—kidney cancer	8.56e-05	0.000186	CcSEcCtD
Sitaxentan—Vomiting—Sorafenib—kidney cancer	8.55e-05	0.000185	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Doxorubicin—kidney cancer	8.55e-05	0.000185	CcSEcCtD
Sitaxentan—Abdominal pain upper—Doxorubicin—kidney cancer	8.55e-05	0.000185	CcSEcCtD
Sitaxentan—Nervous system disorder—Paclitaxel—kidney cancer	8.53e-05	0.000185	CcSEcCtD
Sitaxentan—Thrombocytopenia—Paclitaxel—kidney cancer	8.52e-05	0.000185	CcSEcCtD
Sitaxentan—Tachycardia—Paclitaxel—kidney cancer	8.49e-05	0.000184	CcSEcCtD
Sitaxentan—Rash—Sorafenib—kidney cancer	8.48e-05	0.000184	CcSEcCtD
Sitaxentan—Dermatitis—Sorafenib—kidney cancer	8.48e-05	0.000184	CcSEcCtD
Sitaxentan—Breast disorder—Doxorubicin—kidney cancer	8.46e-05	0.000183	CcSEcCtD
Sitaxentan—Skin disorder—Paclitaxel—kidney cancer	8.45e-05	0.000183	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	8.43e-05	0.000183	CcSEcCtD
Sitaxentan—Headache—Sorafenib—kidney cancer	8.43e-05	0.000183	CcSEcCtD
Sitaxentan—Muscle spasms—Capecitabine—kidney cancer	8.41e-05	0.000182	CcSEcCtD
Sitaxentan—Diarrhoea—Dactinomycin—kidney cancer	8.39e-05	0.000182	CcSEcCtD
Sitaxentan—Anorexia—Paclitaxel—kidney cancer	8.29e-05	0.00018	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GRB7—kidney cancer	8.26e-05	0.000973	CbGpPWpGaD
Sitaxentan—Muscular weakness—Doxorubicin—kidney cancer	8.26e-05	0.000179	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Doxorubicin—kidney cancer	8.26e-05	0.000179	CcSEcCtD
Sitaxentan—Vomiting—Sunitinib—kidney cancer	8.23e-05	0.000178	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—POMC—kidney cancer	8.22e-05	0.000967	CbGpPWpGaD
Sitaxentan—Body temperature increased—Gemcitabine—kidney cancer	8.21e-05	0.000178	CcSEcCtD
Sitaxentan—Tremor—Capecitabine—kidney cancer	8.19e-05	0.000178	CcSEcCtD
Sitaxentan—Rash—Sunitinib—kidney cancer	8.16e-05	0.000177	CcSEcCtD
Sitaxentan—Dermatitis—Sunitinib—kidney cancer	8.16e-05	0.000177	CcSEcCtD
Sitaxentan—Hypotension—Paclitaxel—kidney cancer	8.13e-05	0.000176	CcSEcCtD
Sitaxentan—Ill-defined disorder—Capecitabine—kidney cancer	8.11e-05	0.000176	CcSEcCtD
Sitaxentan—Headache—Sunitinib—kidney cancer	8.11e-05	0.000176	CcSEcCtD
Sitaxentan—Asthma—Doxorubicin—kidney cancer	8.09e-05	0.000175	CcSEcCtD
Sitaxentan—Anaemia—Capecitabine—kidney cancer	8.08e-05	0.000175	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PAK1—kidney cancer	8.08e-05	0.000951	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—JUNB—kidney cancer	8.08e-05	0.000951	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Vincristine—kidney cancer	8.07e-05	0.000175	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTP1—kidney cancer	8.01e-05	0.000943	CbGpPWpGaD
Sitaxentan—Eosinophilia—Doxorubicin—kidney cancer	8.01e-05	0.000174	CcSEcCtD
Sitaxentan—Nausea—Sorafenib—kidney cancer	7.99e-05	0.000173	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTP1—kidney cancer	7.9e-05	0.000931	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	7.9e-05	0.00093	CbGpPWpGaD
Sitaxentan—Malaise—Capecitabine—kidney cancer	7.89e-05	0.000171	CcSEcCtD
Sitaxentan—Angina pectoris—Doxorubicin—kidney cancer	7.88e-05	0.000171	CcSEcCtD
Sitaxentan—Insomnia—Paclitaxel—kidney cancer	7.87e-05	0.000171	CcSEcCtD
Sitaxentan—Vertigo—Capecitabine—kidney cancer	7.86e-05	0.00017	CcSEcCtD
Sitaxentan—Asthenia—Vincristine—kidney cancer	7.86e-05	0.00017	CcSEcCtD
Sitaxentan—Leukopenia—Capecitabine—kidney cancer	7.83e-05	0.00017	CcSEcCtD
Sitaxentan—Vomiting—Dactinomycin—kidney cancer	7.79e-05	0.000169	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—kidney cancer	7.78e-05	0.000169	CcSEcCtD
Sitaxentan—Somnolence—Paclitaxel—kidney cancer	7.73e-05	0.000168	CcSEcCtD
Sitaxentan—Rash—Dactinomycin—kidney cancer	7.73e-05	0.000168	CcSEcCtD
Sitaxentan—Nausea—Sunitinib—kidney cancer	7.69e-05	0.000167	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—ITPR2—kidney cancer	7.68e-05	0.000905	CbGpPWpGaD
Sitaxentan—Pancytopenia—Doxorubicin—kidney cancer	7.68e-05	0.000167	CcSEcCtD
Sitaxentan—Dyspepsia—Paclitaxel—kidney cancer	7.66e-05	0.000166	CcSEcCtD
Sitaxentan—Dysuria—Doxorubicin—kidney cancer	7.57e-05	0.000164	CcSEcCtD
Sitaxentan—Decreased appetite—Paclitaxel—kidney cancer	7.56e-05	0.000164	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Paclitaxel—kidney cancer	7.51e-05	0.000163	CcSEcCtD
Sitaxentan—Fatigue—Paclitaxel—kidney cancer	7.5e-05	0.000163	CcSEcCtD
Sitaxentan—Diarrhoea—Vincristine—kidney cancer	7.49e-05	0.000162	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—kidney cancer	7.47e-05	0.000162	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—POMC—kidney cancer	7.46e-05	0.000878	CbGpPWpGaD
Sitaxentan—Asthenia—Gemcitabine—kidney cancer	7.45e-05	0.000162	CcSEcCtD
Sitaxentan—Chest pain—Capecitabine—kidney cancer	7.45e-05	0.000161	CcSEcCtD
Sitaxentan—Pain—Paclitaxel—kidney cancer	7.44e-05	0.000161	CcSEcCtD
Sitaxentan—Constipation—Paclitaxel—kidney cancer	7.44e-05	0.000161	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	7.39e-05	0.00016	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—kidney cancer	7.38e-05	0.00016	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTM1—kidney cancer	7.36e-05	0.000867	CbGpPWpGaD
Sitaxentan—Discomfort—Capecitabine—kidney cancer	7.36e-05	0.000159	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—kidney cancer	7.32e-05	0.000159	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GSTP1—kidney cancer	7.31e-05	0.00086	CbGpPWpGaD
Sitaxentan—Hyperglycaemia—Doxorubicin—kidney cancer	7.3e-05	0.000158	CcSEcCtD
Sitaxentan—Dry mouth—Capecitabine—kidney cancer	7.28e-05	0.000158	CcSEcCtD
Sitaxentan—Nausea—Dactinomycin—kidney cancer	7.28e-05	0.000158	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.27e-05	0.000856	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTM1—kidney cancer	7.26e-05	0.000855	CbGpPWpGaD
Sitaxentan—Dizziness—Vincristine—kidney cancer	7.24e-05	0.000157	CcSEcCtD
Sitaxentan—Infestation NOS—Doxorubicin—kidney cancer	7.21e-05	0.000156	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—kidney cancer	7.21e-05	0.000156	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	7.21e-05	0.000848	CbGpPWpGaD
Sitaxentan—Confusional state—Capecitabine—kidney cancer	7.2e-05	0.000156	CcSEcCtD
Sitaxentan—Feeling abnormal—Paclitaxel—kidney cancer	7.17e-05	0.000155	CcSEcCtD
Sitaxentan—Oedema—Capecitabine—kidney cancer	7.14e-05	0.000155	CcSEcCtD
Sitaxentan—Diarrhoea—Gemcitabine—kidney cancer	7.11e-05	0.000154	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—kidney cancer	7.09e-05	0.000154	CcSEcCtD
Sitaxentan—Infection—Capecitabine—kidney cancer	7.09e-05	0.000154	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—kidney cancer	7.03e-05	0.000152	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—kidney cancer	7.03e-05	0.000152	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—kidney cancer	7.01e-05	0.000152	CcSEcCtD
Sitaxentan—Nervous system disorder—Capecitabine—kidney cancer	7e-05	0.000152	CcSEcCtD
Sitaxentan—Thrombocytopenia—Capecitabine—kidney cancer	6.99e-05	0.000151	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP1A1—kidney cancer	6.98e-05	0.000822	CbGpPWpGaD
Sitaxentan—Tachycardia—Capecitabine—kidney cancer	6.97e-05	0.000151	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CTNNA1—kidney cancer	6.97e-05	0.00082	CbGpPWpGaD
Sitaxentan—Vomiting—Vincristine—kidney cancer	6.96e-05	0.000151	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—GSTT1—kidney cancer	6.95e-05	0.000819	CbGpPWpGaD
Sitaxentan—Skin disorder—Capecitabine—kidney cancer	6.93e-05	0.00015	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—EIF4EBP1—kidney cancer	6.93e-05	0.000815	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HSPB1—kidney cancer	6.93e-05	0.000815	CbGpPWpGaD
Sitaxentan—Urticaria—Paclitaxel—kidney cancer	6.91e-05	0.00015	CcSEcCtD
Sitaxentan—Rash—Vincristine—kidney cancer	6.9e-05	0.00015	CcSEcCtD
Sitaxentan—Dermatitis—Vincristine—kidney cancer	6.9e-05	0.00015	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1A1—kidney cancer	6.88e-05	0.000811	CbGpPWpGaD
Sitaxentan—Haematuria—Doxorubicin—kidney cancer	6.88e-05	0.000149	CcSEcCtD
Sitaxentan—Body temperature increased—Paclitaxel—kidney cancer	6.88e-05	0.000149	CcSEcCtD
Sitaxentan—Headache—Vincristine—kidney cancer	6.86e-05	0.000149	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—kidney cancer	6.82e-05	0.000148	CcSEcCtD
Sitaxentan—Epistaxis—Doxorubicin—kidney cancer	6.8e-05	0.000147	CcSEcCtD
Sitaxentan—Anorexia—Capecitabine—kidney cancer	6.8e-05	0.000147	CcSEcCtD
Sitaxentan—Sinusitis—Doxorubicin—kidney cancer	6.77e-05	0.000147	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GSTM1—kidney cancer	6.71e-05	0.000791	CbGpPWpGaD
Sitaxentan—Hypotension—Capecitabine—kidney cancer	6.67e-05	0.000145	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	6.62e-05	0.00078	CbGpPWpGaD
Sitaxentan—Vomiting—Gemcitabine—kidney cancer	6.6e-05	0.000143	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—IGF2—kidney cancer	6.6e-05	0.000777	CbGpPWpGaD
Sitaxentan—Bradycardia—Doxorubicin—kidney cancer	6.59e-05	0.000143	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CDKN2B—kidney cancer	6.57e-05	0.000774	CbGpPWpGaD
Sitaxentan—Rash—Gemcitabine—kidney cancer	6.55e-05	0.000142	CcSEcCtD
Sitaxentan—Dermatitis—Gemcitabine—kidney cancer	6.54e-05	0.000142	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—PTGS1—kidney cancer	6.51e-05	0.000767	CbGpPWpGaD
Sitaxentan—Haemoglobin—Doxorubicin—kidney cancer	6.51e-05	0.000141	CcSEcCtD
Sitaxentan—Headache—Gemcitabine—kidney cancer	6.51e-05	0.000141	CcSEcCtD
Sitaxentan—Nausea—Vincristine—kidney cancer	6.5e-05	0.000141	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—kidney cancer	6.49e-05	0.000141	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—kidney cancer	6.48e-05	0.00014	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—kidney cancer	6.48e-05	0.00014	CcSEcCtD
Sitaxentan—Insomnia—Capecitabine—kidney cancer	6.46e-05	0.00014	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PSMD7—kidney cancer	6.44e-05	0.000758	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TSC1—kidney cancer	6.44e-05	0.000758	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ANXA1—kidney cancer	6.44e-05	0.000758	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Paclitaxel—kidney cancer	6.41e-05	0.000139	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—kidney cancer	6.39e-05	0.000139	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—IGF1R—kidney cancer	6.38e-05	0.000752	CbGpPWpGaD
Sitaxentan—Oedema peripheral—Doxorubicin—kidney cancer	6.38e-05	0.000138	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	6.37e-05	0.000749	CbGpPWpGaD
Sitaxentan—Urethral disorder—Doxorubicin—kidney cancer	6.35e-05	0.000138	CcSEcCtD
Sitaxentan—Dyspepsia—Capecitabine—kidney cancer	6.28e-05	0.000136	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	6.28e-05	0.000739	CbGpPWpGaD
Sitaxentan—Visual impairment—Doxorubicin—kidney cancer	6.24e-05	0.000135	CcSEcCtD
Sitaxentan—Asthenia—Paclitaxel—kidney cancer	6.24e-05	0.000135	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—FLT1—kidney cancer	6.24e-05	0.000734	CbGpPWpGaD
Sitaxentan—Decreased appetite—Capecitabine—kidney cancer	6.2e-05	0.000134	CcSEcCtD
Sitaxentan—Nausea—Gemcitabine—kidney cancer	6.17e-05	0.000134	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Capecitabine—kidney cancer	6.16e-05	0.000134	CcSEcCtD
Sitaxentan—Fatigue—Capecitabine—kidney cancer	6.15e-05	0.000133	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—RAF1—kidney cancer	6.15e-05	0.000724	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ACY1—kidney cancer	6.14e-05	0.000723	CbGpPWpGaD
Sitaxentan—Pain—Capecitabine—kidney cancer	6.1e-05	0.000132	CcSEcCtD
Sitaxentan—Constipation—Capecitabine—kidney cancer	6.1e-05	0.000132	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—kidney cancer	6.07e-05	0.000715	CbGpPWpGaD
Sitaxentan—Eye disorder—Doxorubicin—kidney cancer	6.05e-05	0.000131	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—kidney cancer	6.04e-05	0.000131	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—kidney cancer	6.01e-05	0.00013	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—kidney cancer	6.01e-05	0.00013	CcSEcCtD
Sitaxentan—Diarrhoea—Paclitaxel—kidney cancer	5.95e-05	0.000129	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.89e-05	0.000694	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Capecitabine—kidney cancer	5.88e-05	0.000127	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—POMC—kidney cancer	5.88e-05	0.000692	CbGpPWpGaD
Sitaxentan—Angiopathy—Doxorubicin—kidney cancer	5.88e-05	0.000127	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—kidney cancer	5.85e-05	0.000127	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—kidney cancer	5.84e-05	0.000127	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—JUNB—kidney cancer	5.78e-05	0.000681	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PAK1—kidney cancer	5.78e-05	0.000681	CbGpPWpGaD
Sitaxentan—Dizziness—Paclitaxel—kidney cancer	5.75e-05	0.000125	CcSEcCtD
Sitaxentan—Alopecia—Doxorubicin—kidney cancer	5.72e-05	0.000124	CcSEcCtD
Sitaxentan—Mental disorder—Doxorubicin—kidney cancer	5.67e-05	0.000123	CcSEcCtD
Sitaxentan—Urticaria—Capecitabine—kidney cancer	5.67e-05	0.000123	CcSEcCtD
Sitaxentan—Body temperature increased—Capecitabine—kidney cancer	5.64e-05	0.000122	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—kidney cancer	5.64e-05	0.000122	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—ACY1—kidney cancer	5.6e-05	0.000659	CbGpPWpGaD
Sitaxentan—Tension—Doxorubicin—kidney cancer	5.53e-05	0.00012	CcSEcCtD
Sitaxentan—Vomiting—Paclitaxel—kidney cancer	5.53e-05	0.00012	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—kidney cancer	5.52e-05	0.000649	CbGpPWpGaD
Sitaxentan—Rash—Paclitaxel—kidney cancer	5.48e-05	0.000119	CcSEcCtD
Sitaxentan—Dermatitis—Paclitaxel—kidney cancer	5.48e-05	0.000119	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—kidney cancer	5.47e-05	0.000119	CcSEcCtD
Sitaxentan—Headache—Paclitaxel—kidney cancer	5.45e-05	0.000118	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—kidney cancer	5.42e-05	0.000117	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—POMC—kidney cancer	5.34e-05	0.000629	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Capecitabine—kidney cancer	5.26e-05	0.000114	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HIF1A—kidney cancer	5.26e-05	0.000619	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TSC2—kidney cancer	5.24e-05	0.000617	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	5.24e-05	0.000617	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Doxorubicin—kidney cancer	5.23e-05	0.000113	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—PDHB—kidney cancer	5.22e-05	0.000615	CbGpPWpGaD
Sitaxentan—Anaemia—Doxorubicin—kidney cancer	5.21e-05	0.000113	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—POMC—kidney cancer	5.2e-05	0.000613	CbGpPWpGaD
Sitaxentan—Agitation—Doxorubicin—kidney cancer	5.18e-05	0.000112	CcSEcCtD
Sitaxentan—Nausea—Paclitaxel—kidney cancer	5.17e-05	0.000112	CcSEcCtD
Sitaxentan—Asthenia—Capecitabine—kidney cancer	5.12e-05	0.000111	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—kidney cancer	5.08e-05	0.00011	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—kidney cancer	5.06e-05	0.00011	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—kidney cancer	5.05e-05	0.000109	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—KDR—kidney cancer	5.03e-05	0.000592	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CCBL1—kidney cancer	4.91e-05	0.000578	CbGpPWpGaD
Sitaxentan—Diarrhoea—Capecitabine—kidney cancer	4.88e-05	0.000106	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—GSTP1—kidney cancer	4.82e-05	0.000567	CbGpPWpGaD
Sitaxentan—Chest pain—Doxorubicin—kidney cancer	4.8e-05	0.000104	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	4.77e-05	0.000562	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.77e-05	0.000103	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—PDHB—kidney cancer	4.76e-05	0.000561	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	4.75e-05	0.00056	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—POMC—kidney cancer	4.75e-05	0.000559	CbGpPWpGaD
Sitaxentan—Discomfort—Doxorubicin—kidney cancer	4.74e-05	0.000103	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—IGF2—kidney cancer	4.73e-05	0.000556	CbGpPWpGaD
Sitaxentan—Dizziness—Capecitabine—kidney cancer	4.72e-05	0.000102	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CDKN2B—kidney cancer	4.71e-05	0.000554	CbGpPWpGaD
Sitaxentan—Dry mouth—Doxorubicin—kidney cancer	4.69e-05	0.000102	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—kidney cancer	4.64e-05	0.000101	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—APC—kidney cancer	4.63e-05	0.000545	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KIT—kidney cancer	4.63e-05	0.000545	CbGpPWpGaD
Sitaxentan—Oedema—Doxorubicin—kidney cancer	4.6e-05	9.97e-05	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—kidney cancer	4.57e-05	9.91e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—IGF1R—kidney cancer	4.57e-05	0.000538	CbGpPWpGaD
Sitaxentan—Vomiting—Capecitabine—kidney cancer	4.54e-05	9.84e-05	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—kidney cancer	4.51e-05	9.78e-05	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—kidney cancer	4.5e-05	9.76e-05	CcSEcCtD
Sitaxentan—Rash—Capecitabine—kidney cancer	4.5e-05	9.76e-05	CcSEcCtD
Sitaxentan—Dermatitis—Capecitabine—kidney cancer	4.5e-05	9.75e-05	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—kidney cancer	4.49e-05	9.73e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—CCBL1—kidney cancer	4.48e-05	0.000527	CbGpPWpGaD
Sitaxentan—Headache—Capecitabine—kidney cancer	4.47e-05	9.69e-05	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—kidney cancer	4.47e-05	9.69e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.44e-05	0.000523	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK3—kidney cancer	4.43e-05	0.000522	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTM1—kidney cancer	4.43e-05	0.000521	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—POMC—kidney cancer	4.41e-05	0.000519	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—RAF1—kidney cancer	4.4e-05	0.000518	CbGpPWpGaD
Sitaxentan—Anorexia—Doxorubicin—kidney cancer	4.39e-05	9.51e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	4.37e-05	0.000514	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BRAF—kidney cancer	4.35e-05	0.000512	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—kidney cancer	4.35e-05	0.000512	CbGpPWpGaD
Sitaxentan—Hypotension—Doxorubicin—kidney cancer	4.3e-05	9.32e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—GLIPR1—kidney cancer	4.26e-05	0.000501	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPAT—kidney cancer	4.26e-05	0.000501	CbGpPWpGaD
Sitaxentan—Nausea—Capecitabine—kidney cancer	4.24e-05	9.19e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK1—kidney cancer	4.22e-05	0.000497	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.2e-05	0.000495	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	4.2e-05	0.000494	CbGpPWpGaD
Sitaxentan—Insomnia—Doxorubicin—kidney cancer	4.16e-05	9.02e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.16e-05	0.00049	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	4.14e-05	0.000487	CbGpPWpGaD
Sitaxentan—Somnolence—Doxorubicin—kidney cancer	4.09e-05	8.87e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—kidney cancer	4.05e-05	8.78e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.05e-05	0.000477	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CA—kidney cancer	4.03e-05	0.000475	CbGpPWpGaD
Sitaxentan—Decreased appetite—Doxorubicin—kidney cancer	4e-05	8.67e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—kidney cancer	3.99e-05	0.000469	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.97e-05	8.61e-05	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—kidney cancer	3.97e-05	8.6e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—APRT—kidney cancer	3.96e-05	0.000466	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—FH—kidney cancer	3.96e-05	0.000466	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—kidney cancer	3.95e-05	0.000465	CbGpPWpGaD
Sitaxentan—Pain—Doxorubicin—kidney cancer	3.93e-05	8.53e-05	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—kidney cancer	3.93e-05	8.53e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—PPAT—kidney cancer	3.88e-05	0.000457	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GLIPR1—kidney cancer	3.88e-05	0.000457	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	3.87e-05	0.000455	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	3.83e-05	0.000451	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	3.79e-05	0.000447	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Doxorubicin—kidney cancer	3.79e-05	8.22e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HIF1A—kidney cancer	3.76e-05	0.000443	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TSC2—kidney cancer	3.75e-05	0.000442	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPC3—kidney cancer	3.72e-05	0.000438	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ACY1—kidney cancer	3.69e-05	0.000435	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CA—kidney cancer	3.66e-05	0.000431	CbGpPWpGaD
Sitaxentan—Urticaria—Doxorubicin—kidney cancer	3.65e-05	7.92e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—kidney cancer	3.64e-05	7.88e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RAF1—kidney cancer	3.63e-05	0.000428	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA2—kidney cancer	3.62e-05	0.000426	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RELA—kidney cancer	3.62e-05	0.000426	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—APRT—kidney cancer	3.61e-05	0.000425	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—FH—kidney cancer	3.61e-05	0.000425	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KDR—kidney cancer	3.6e-05	0.000424	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ERBB2—kidney cancer	3.6e-05	0.000423	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MTOR—kidney cancer	3.55e-05	0.000418	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALAD—kidney cancer	3.53e-05	0.000415	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	3.53e-05	0.000415	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ST3GAL2—kidney cancer	3.44e-05	0.000405	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPC3—kidney cancer	3.39e-05	0.000399	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Doxorubicin—kidney cancer	3.39e-05	7.35e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—ALDH1A1—kidney cancer	3.36e-05	0.000396	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1B—kidney cancer	3.33e-05	0.000392	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KIT—kidney cancer	3.31e-05	0.00039	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APC—kidney cancer	3.31e-05	0.00039	CbGpPWpGaD
Sitaxentan—Asthenia—Doxorubicin—kidney cancer	3.3e-05	7.16e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—CA2—kidney cancer	3.3e-05	0.000389	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—kidney cancer	3.26e-05	0.000384	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PGK1—kidney cancer	3.23e-05	0.00038	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC5A3—kidney cancer	3.23e-05	0.00038	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALAD—kidney cancer	3.22e-05	0.000379	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—kidney cancer	3.18e-05	0.000374	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK3—kidney cancer	3.17e-05	0.000374	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—JUN—kidney cancer	3.17e-05	0.000373	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—LDHB—kidney cancer	3.16e-05	0.000372	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—POMC—kidney cancer	3.15e-05	0.000371	CbGpPWpGaD
Sitaxentan—Diarrhoea—Doxorubicin—kidney cancer	3.15e-05	6.82e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CTNNB1—kidney cancer	3.15e-05	0.00037	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PDHB—kidney cancer	3.14e-05	0.00037	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ST3GAL2—kidney cancer	3.14e-05	0.00037	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—POMC—kidney cancer	3.13e-05	0.000369	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—kidney cancer	3.11e-05	0.000367	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALDH1A1—kidney cancer	3.07e-05	0.000361	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—kidney cancer	3.07e-05	0.000361	CbGpPWpGaD
Sitaxentan—Dizziness—Doxorubicin—kidney cancer	3.04e-05	6.59e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK1—kidney cancer	3.02e-05	0.000356	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CCBL1—kidney cancer	2.95e-05	0.000348	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PGK1—kidney cancer	2.94e-05	0.000346	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC5A3—kidney cancer	2.94e-05	0.000346	CbGpPWpGaD
Sitaxentan—Vomiting—Doxorubicin—kidney cancer	2.93e-05	6.34e-05	CcSEcCtD
Sitaxentan—Rash—Doxorubicin—kidney cancer	2.9e-05	6.29e-05	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—kidney cancer	2.9e-05	6.28e-05	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—kidney cancer	2.89e-05	0.00034	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—LDHB—kidney cancer	2.88e-05	0.00034	CbGpPWpGaD
Sitaxentan—Headache—Doxorubicin—kidney cancer	2.88e-05	6.25e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—kidney cancer	2.85e-05	0.000336	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—kidney cancer	2.77e-05	0.000326	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA9—kidney cancer	2.74e-05	0.000323	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—kidney cancer	2.73e-05	5.92e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.68e-05	0.000316	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—kidney cancer	2.62e-05	0.000309	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK3—kidney cancer	2.62e-05	0.000308	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RAF1—kidney cancer	2.6e-05	0.000306	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RELA—kidney cancer	2.59e-05	0.000305	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB2—kidney cancer	2.57e-05	0.000303	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GLIPR1—kidney cancer	2.56e-05	0.000301	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPAT—kidney cancer	2.56e-05	0.000301	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—kidney cancer	2.55e-05	0.0003	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MTOR—kidney cancer	2.54e-05	0.000299	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA9—kidney cancer	2.5e-05	0.000294	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK1—kidney cancer	2.49e-05	0.000293	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.44e-05	0.000288	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1B—kidney cancer	2.38e-05	0.000281	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APRT—kidney cancer	2.38e-05	0.00028	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—FH—kidney cancer	2.38e-05	0.00028	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—kidney cancer	2.35e-05	0.000277	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CRABP1—kidney cancer	2.33e-05	0.000275	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—kidney cancer	2.33e-05	0.000275	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—kidney cancer	2.27e-05	0.000268	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—JUN—kidney cancer	2.27e-05	0.000267	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNB1—kidney cancer	2.25e-05	0.000265	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPC3—kidney cancer	2.24e-05	0.000263	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—kidney cancer	2.19e-05	0.000258	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA2—kidney cancer	2.18e-05	0.000256	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ITPR2—kidney cancer	2.17e-05	0.000255	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—kidney cancer	2.16e-05	0.000255	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CRABP1—kidney cancer	2.13e-05	0.00025	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALAD—kidney cancer	2.12e-05	0.00025	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—kidney cancer	2.09e-05	0.000246	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ST3GAL2—kidney cancer	2.07e-05	0.000244	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.02e-05	0.000238	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2e-05	0.000235	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—kidney cancer	1.98e-05	0.000233	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTT1—kidney cancer	1.98e-05	0.000233	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ACHE—kidney cancer	1.98e-05	0.000233	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ITPR2—kidney cancer	1.98e-05	0.000233	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PGK1—kidney cancer	1.94e-05	0.000228	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.94e-05	0.000228	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—LDHB—kidney cancer	1.9e-05	0.000224	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK3—kidney cancer	1.87e-05	0.000221	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SCARB1—kidney cancer	1.87e-05	0.00022	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS1—kidney cancer	1.85e-05	0.000218	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—kidney cancer	1.82e-05	0.000215	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.82e-05	0.000215	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PSMD7—kidney cancer	1.82e-05	0.000214	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTT1—kidney cancer	1.8e-05	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ACHE—kidney cancer	1.8e-05	0.000212	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK1—kidney cancer	1.78e-05	0.00021	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—BCHE—kidney cancer	1.72e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SCARB1—kidney cancer	1.71e-05	0.000201	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC5A5—kidney cancer	1.7e-05	0.0002	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS1—kidney cancer	1.69e-05	0.000199	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—kidney cancer	1.68e-05	0.000198	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PSMD7—kidney cancer	1.66e-05	0.000195	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA9—kidney cancer	1.65e-05	0.000194	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC2A1—kidney cancer	1.64e-05	0.000193	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.59e-05	0.000188	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—BCHE—kidney cancer	1.57e-05	0.000185	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC5A5—kidney cancer	1.55e-05	0.000183	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—kidney cancer	1.55e-05	0.000182	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC2A1—kidney cancer	1.5e-05	0.000176	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—kidney cancer	1.5e-05	0.000176	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.45e-05	0.000171	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CRABP1—kidney cancer	1.4e-05	0.000165	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.39e-05	0.000164	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—kidney cancer	1.37e-05	0.000161	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ITPR2—kidney cancer	1.3e-05	0.000154	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCB1—kidney cancer	1.3e-05	0.000153	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.27e-05	0.000149	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—kidney cancer	1.26e-05	0.000148	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—kidney cancer	1.25e-05	0.000147	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1A1—kidney cancer	1.19e-05	0.000141	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ACHE—kidney cancer	1.19e-05	0.00014	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTT1—kidney cancer	1.19e-05	0.00014	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCB1—kidney cancer	1.18e-05	0.000139	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—kidney cancer	1.15e-05	0.000135	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SCARB1—kidney cancer	1.13e-05	0.000133	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS1—kidney cancer	1.11e-05	0.000131	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PSMD7—kidney cancer	1.09e-05	0.000129	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1A1—kidney cancer	1.09e-05	0.000128	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—BCHE—kidney cancer	1.04e-05	0.000122	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.02e-05	0.00012	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC2A1—kidney cancer	9.88e-06	0.000116	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.81e-06	0.000115	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.94e-06	0.000105	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—POMC—kidney cancer	8.9e-06	0.000105	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—kidney cancer	8.24e-06	9.7e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—POMC—kidney cancer	8.12e-06	9.56e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCB1—kidney cancer	7.8e-06	9.18e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—kidney cancer	7.57e-06	8.92e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1A1—kidney cancer	7.18e-06	8.45e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—kidney cancer	7.1e-06	8.36e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—kidney cancer	6.47e-06	7.62e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—kidney cancer	6.19e-06	7.29e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—kidney cancer	5.65e-06	6.65e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—POMC—kidney cancer	5.35e-06	6.3e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—kidney cancer	4.37e-06	5.14e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—kidney cancer	4.27e-06	5.03e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—kidney cancer	3.98e-06	4.69e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—kidney cancer	3.72e-06	4.38e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—kidney cancer	2.63e-06	3.09e-05	CbGpPWpGaD
